-
Taxonomy & unit
-
us-gaap: USD
-
Description
-
The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.
-
Summary
-
Immix Biopharma, Inc. quarterly/annual Net Income (Loss) Attributable to Parent history and growth rate from Q1 2021 to Q2 2024.
- Immix Biopharma, Inc. Net Income (Loss) Attributable to Parent for the quarter ending June 30, 2024 was -$4.39M, a 22.8% decline year-over-year.
- Immix Biopharma, Inc. Net Income (Loss) Attributable to Parent for the twelve months ending June 30, 2024 was -$19M, a 67% decline year-over-year.
- Immix Biopharma, Inc. annual Net Income (Loss) Attributable to Parent for 2023 was -$15.4M, a 87.4% decline from 2022.
- Immix Biopharma, Inc. annual Net Income (Loss) Attributable to Parent for 2022 was -$8.23M, a 66.2% increase from 2021.
- Immix Biopharma, Inc. annual Net Income (Loss) Attributable to Parent for 2021 was -$24.4M, a 2024% decline from 2020.
Net Income (Loss) Attributable to Parent, Trailing 12 Months (USD)
Net Income (Loss) Attributable to Parent, Quarterly (USD)
Net Income (Loss) Attributable to Parent, YoY Quarterly Growth (%)